Gene expression profiling identifies matriptase overexpression in malignant mesothelioma

Chest

Volumn 125, Issue 5, 2004, Pages 1843-1852

  Hoang, Chuong D ^a   D'Cunha, Jonathan ^a   Kratzke, Marian G ^b   Casmey, Carrie E ^a   Frizelle, Sandra P ^b   Maddaus, Michael A ^a   Kratzke, Robert A ^b,c  

^a Div Cardiovasc and Thorac Surg   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Expression profiling; Matriptase; Mesothelioma; Microarray; Real time polymerase chain reaction

Indexed keywords

COMPLEMENTARY DNA; ENZYME; MATRIPTASE; MESSENGER RNA; PROTEOLIPID; SOMATOMEDIN BINDING PROTEIN 5; UNCLASSIFIED DRUG;

ARTICLE; CANCER INVASION; CARCINOGENESIS; CELL LINE; CLUSTER ANALYSIS; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION; GENE OVEREXPRESSION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; MALIGNANT MESOTHELIOMA; METASTASIS; NUCLEOTIDE SEQUENCE; PLEURA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

EID: 2442432225     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.125.5.1843     Document Type: Article

References (49)

1. Britton M. The epidemiology of mesothelioma. Semin Oncol 2002; 29:18-25
2. Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin Oncol 2002; 29:2-17
3. Steele JP. Prognostic factors in mesothelioma. Semin Oncol 2002; 29:36-40
4. Steele JP, Shamash J, Evans MT, et al. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 2000; 18:3912-3917
5. Mossman BT, Churg A. Mechanisms in the pathogenesis of asbestosis and silicosis. Am J Respir Crit Care Med 1998; 157:1666-1680
6. Testa JR, Pass HI, Carbone M, Molecular biology of mesothelioma. In: DeVita V, Hellman S, Rosenberg S, eds. Principles and practice of oncology. Philadelphia, PA: Lippincott, 2001; 1937-1943
7. Rihn BH, Mohr S, McDowell SA, et al. Differential gene expression in mesothelioma. FEES Lett 2000; 480:95-100
8. Kettunen E, Nissen AM, Ollikainen T, et al. Gene expression profiling of malignant mesothelioma cell lines: cDNA array study. Int J Cancer 2001; 91:492-496
9. Oberst M, Anders J, Xie B, et al. Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am J Pathol 2001; 158:1301-1311
10. Pass HI, Stevens EJ, Oie H, et al. Characteristics of nine newly derived mesothelioma cell lines. Ann Thorac Surg 1995; 59:835-844
11. D'Cunha J, Corfits AL, Herndon JE II, et al. Molecular staging of lung cancer: real-time polymerase chain reaction estimation of lymph node micrometastatic rumor cell burden in stage I non-small cell lung cancer; preliminary results of Cancer and Leukemia Group B Trial 9761. J Thorac Cardiovasc Surg 2002; 123:484-491
12. Kricka LJ. Ultrasensitive immunoassay techniques. Clin Biochem 1993; 26:325-331
13. Litt GJ, Bobrow MN. Tyramide signal amplification: applications in the detection of infectious agents. In: Specter S, Bendinelli M, Friedman H, eds. Rapid detection of infectious agents. New York, NY: Plenum Press, 1998; 159-173
14. Sugita M, Geraci M, Gao B, et al. Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma. Cancer Res 2002; 62:3971-3979
15. Eisen MB, Spellman PT, Brown PO, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998; 95:14863-14868
16. Weinstein JN, Myers TG, O'Connor PM, et al. An information-intensive approach to the molecular pharmacology of cancer. Science 1997; 275:343-349
17. Gerard CJ, Andrejka LM, Macina RA. Mitochondrial ATP synthase 6 as an endogenous control in die quantitative RT-PCR analysis of clinical cancer samples. Mol Diagn 2000; 5:39-46
18. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(t)) method. Methods 2001; 25:402-408
19. Heid CA, Stevens J, Livak KJ, et al. Real time quantitative PCR. Genome Res 1996; 6:986-994
20. Frizelle SP, Grim J, Zhou J, et al. Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression. Oncogene 1998; 16:3087-0095
21. Benaud CM, Dickson RB, Lin CY. Regulation of the activity of matriptase on epithelial cell surfaces by a blood-derived factor. Eur J Biochem 2001; 268:1439-1447
22. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mHNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 2001; 98:13790-13795
23. Sorlie T, Perou CM, Tibshirani H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98:10869-10874
24. Quackenbush J. Computational analysis of microarray data. Nat Rev Genet 2001; 2:418-427
25. Gordon GJ, Jensen RV, Hsiao LL, et al. Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res 2002; 62:4963-4967
26. Gordon GJ, Jensen RV, Hsiao LL, et al. Using gene expression ratios to predict outcome among patients with mesothelioma. J Natl Cancer Inst 2003; 95:598-605
27. Takeuchi T, Shuman MA, Craik CS. Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc Natl Acad Sci U S A 1999; 96:11054-11061
28. Benaud CM, Oberst M, Dickson RB, et al. Deregulated activation of matriptase in breast cancer cells. Clin Exp Metastasis 2002; 19:639-649
29. Oberst MD, Johnson MD, Dickson RB, et al. Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. Clin Cancer Res 2002; 8:1101-1107
30. Lee SL, Dickson RB, Lin CY. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 2000; 275:36720-36725
31. Takeuchi T, Harris JL, Huang W, et al. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 2000; 275:26333-26342
32. Grimberg A, Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol 2000; 183:1-9
33. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002; 23:824-854
34. Grimberg A, Cohen P. Growth hormone and prostate cancer: guilty by association? J Endocrinol Invest 1999; 22:64-73
35. Allen JT, Bloor CA, Kedia RK, et al. Expression of growth hormone-releasing factor, growth hormone, insulin-like growth factor-1 and its binding proteins in human lung. Neuropeptides 2000; 34:98-107
36. Quinn KA, Treston AM, Unsworth EJ, et al. Insulin-like growth factor expression in human cancer cell lines. J Biol Chem 1996; 271:11477-11483
37. Reinmuth N, Fan F, Liu W, et al. Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest 2002; 82:1377-1389
38. Schneider MR, Wolf E, Hoeflich A, et al. IGF-binding protein-5: flexible player in the IGF system and effector on its own. J Endocrinol 2002; 172:423-440
39. Miyake H, Nelson C, Rennie PS, et al. Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3′-kinase pathway. Endocrinology 2000; 141:2257-2265
40. Perks CM, McCaig C, Holly JM. Differential insulin-like growth factor (IGF)-independent interactions of IGF binding protein-3 and IGF binding protein-5 on apoptosis in human breast cancer cells: involvement of the mitochondria. J Cell Biochem 2000; 80:248-258
41. Higo H, Duan C, Clemmons DR, et al. Retinoic acid inhibits cell growth in HPV negative cervical carcinoma cells by induction of insulin-like growth factor binding protein-5 (IGFBP-5) secretion. Biochem Biophys Res Commun 1997; 239:706-709
42. Conover CA, Kiefer MC. Regulation and biological effect of endogenous insulin-like growth factor binding protein-5 in human osteoblastic cells. J Clin Endocrinol Metab 1993; 76:1153-1159
43. Copie-Bergman C, Plonquet A, Alonso MA, et al. MAL expression in lymphoid cells: further evidence for MAL as a distinct molecular marker of primary mediastinal large B-cell lymphomas. Mod Pathol 2002; 15:1172-1180
44. Marazuela M, Acevedo A, Adrados M, et al. Expression of MAL, an integral protein component of the machinery for raft-mediated pical transport, in human epithelia. J Histochem Cytochem 2003; 51:665-674
45. de Marco MC, Martin-Belmonte F, Kremer L, et al. MAL2, a novel raft protein of the MAL family, is an essential component of the machinery for transcytosis in hepatoma HepG2 cells. J Cell Biol 2002; 159:37-44
46. Holloway AJ, van Laar RK, Tothill RW, et al. Options available-from start to finish-for obtaining data from DNA microarrays II. Nat Genet 2002; 32(suppl):481-489
47. Ross DT, Scherf U, Eisen MB, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000; 24:227-235
48. Kikuchi T, Daigo Y, Katagiri T, et al. Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 2003; 22:2192-2205
49. Miura K, Bowman ED, Simon R, et al. Laser capture microdissection and microarray expression analysis of lung adenocarcinoma reveals tobacco smoking- and prognosis-related molecular profiles. Cancer Res 2002; 62:3244-3250